Accuray Incorp Stock Price, News & Analysis

Accuray Incorporated (NASDAQ: ARAY) will report its financial results for the first quarter of fiscal year 2021, ending September 30, 2020. The announcement will be made after the market closes on October 29, 2020. Management will conduct a conference call at 1:30 p.m. PT on the same day to discuss the results. Dial-in details are provided for both domestic and international participants. A live webcast will also be available on the company’s Investor Relations website, with a replay accessible until the next quarterly results are announced.

Accuray Incorporated (NASDAQ: ARAY) will host an Analyst & Investor Meeting on October 26, 2020, in conjunction with the ASTRO Annual Meeting. The virtual event will run from 1:00 pm ET to 3:00 pm ET. Management will discuss the company's growth strategies focused on advancing radiation therapy, featuring insights from physician guest speakers. Registration is required by October 20, 2020, and a replay will be available post-event on Accuray's website.

Accuray Incorporated (NASDAQ: ARAY) has announced that several leading hospitals in Japan are now utilizing its Radixact® System combined with Synchrony® Automatic, Real-time Motion Synchronization Technology for advanced cancer treatments. This technology allows more precise treatment of tumors that move, reducing radiation exposure to healthy tissue. Notably, Takarazuka City Hospital treated the first Synchrony patient in Asia and was the first globally to perform a liver treatment with this technology. The adoption of these systems in Japan, which has the highest penetration of such innovations, aims to enhance cancer care and treatment outcomes.

Accuray Incorporated (NASDAQ: ARAY) will present at the Lake Street Capital Markets Best Ideas Growth (BIG4) Conference on September 17, 2020. CEO Joshua H. Levine and CFO Shig Hamamatsu are set to share insights with institutional investors during this virtual event. Prior to the conference, management will engage in various one-on-one and group discussions throughout the day. For more information, visit Lake Street Capital Markets.

Accuray Incorporated (NASDAQ: ARAY) has announced a significant milestone with the University Hospital Città della Salute e della Scienza in Turin, Italy, successfully treating the first cancer patients in the EIMEA region using the Radixact® System featuring Synchrony® technology. This innovative approach allows for personalized cancer care by adapting treatment based on real-time patient movements, enhancing the precision of radiation therapy. The first patient treated was an 85-year-old man with early-stage lung cancer, benefiting from the system's ability to minimize harm to healthy tissues.

Accuray reported its Q4 and fiscal year 2020 results, highlighting gross orders of $94.3 million and a net revenue of $95.0 million. The company experienced a net loss of $0.8 million for Q4, while fiscal year net income reached $3.2 million. Notably, gross product orders increased by 10% to $377.3 million year-over-year, with an ending backlog of $602.7 million, up 22%. However, the company refrained from providing guidance for fiscal 2021 due to uncertainties surrounding COVID-19.

Accuray Incorporated (NASDAQ: ARAY) announced the appointment of Anne B. Le Grand to its Board of Directors, effective July 16, 2020. Ms. Le Grand brings over 25 years of experience in the healthcare technology sector, previously serving at IBM Watson Health Imaging and Philips Health Systems. Her role aims to enhance Accuray's product innovation in radiation therapy. CEO Joshua H. Levine highlighted her track record in launching market-driven products vital for financial growth. This strategic addition to the board reflects Accuray's commitment to improving cancer treatment.

Accuray Incorporated (NASDAQ: ARAY) will announce its financial results for Q4 and fiscal year 2020, ending June 30, on August 13, 2020. The announcement will take place after market close, followed by a conference call at 1:30 p.m. PT/4:30 p.m. ET. Investors can access a live webcast and a replay on the company’s website. Accuray develops advanced radiotherapy systems aimed at improving cancer treatment outcomes.

Accuray Incorporated (NASDAQ: ARAY) launched the CyberKnife S7 System on June 17, 2020, a robotic, non-invasive radiation therapy device designed for faster and more accurate treatment of tumors. This innovative system integrates real-time AI-driven motion tracking, allowing for treatments to be delivered in as little as 15 minutes. Geisinger Cancer Institute is the first center globally to utilize this technology, enhancing patient care by adapting to patient movement. Moreover, changes in Medicare & Medicaid favor hypofractionated radiotherapy, positioning CyberKnife as a valuable tool for hospitals aiming for clinical effectiveness and return on investment.